1. Doxycycline reversal of amphetamine-induced mania-like behavior is related to adjusting brain monoamine abnormalities and antioxidant effects in primary hippocampal neurons.
- Author
-
Chaves-Filho AJM, Soares MV, Jucá PM, Oliveira TQ, Clemente DCDS, Monteiro CEDS, Silva FGO, de Aquino PEA, and Macedo DS
- Subjects
- Animals, Male, Mice, Behavior, Animal drug effects, Cells, Cultured, Amphetamine pharmacology, Amphetamine toxicity, Disease Models, Animal, Central Nervous System Stimulants toxicity, Biogenic Monoamines metabolism, Dextroamphetamine pharmacology, Dextroamphetamine toxicity, Antimanic Agents pharmacology, Neuroprotective Agents pharmacology, Neurons drug effects, Neurons metabolism, Hippocampus drug effects, Hippocampus metabolism, Antioxidants pharmacology, Mania chemically induced, Mania drug therapy, Doxycycline pharmacology
- Abstract
Mania is associated with disturbed dopaminergic transmission in frontotemporal regions. D-amphetamine (AMPH) causes increased extracellular DA levels, considered an acknowledged mania model in rodents. Doxycycline (DOXY) is a second-generation tetracycline with promising neuroprotective properties. Here, we tested the hypothesis that DOXY alone or combined with Lithium (Li) could reverse AMPH-induced mania-like behavioral alterations in mice by the modulation of monoamine levels in brain areas related to mood regulation, as well as cytoprotective and antioxidant effects in hippocampal neurons. Male Swiss mice received AMPH or saline intraperitoneal (IP) injections for 14 days. Between days 8-14, mice receive further IP doses of DOXY, Li, or their combination. For in vitro studies, we exposed hippocampal neurons to DOXY in the presence or absence of AMPH. DOXY alone or combined with Li reversed AMPH-induced risk-taking behavior and hyperlocomotion. DOXY also reversed AMPH-induced hippocampal and striatal hyperdopaminergia. In AMPH-exposed hippocampal neurons, DOXY alone and combined with Li presented cytoprotective and antioxidant effects, while DOXY+Li also increased the expression of phospho-Ser133-CREB. Our results add novel evidence for DOXY's ability to reverse mania-like features while revealing that antidopaminergic activity in some brain areas, such as the hippocampus and striatum, as well as hippocampal cytoprotective effects may account for this drug's antimanic action. This study provides additional rationale for designing clinical trials investigating its potential as a mood stabilizer agent., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF